China National Biotec Group Plans Hong Kong IPO
This article was originally published in PharmAsia News
You may also be interested in...
Experience and data from the study, which will use the same vector platform to deliver different transgenes for different diseases, could feed into the US FDA’s efforts to establish a public-private partnership to enable manufacturing of gene therapies for ultra-rare diseases.
Non-Hygiene Personal Care ‘Essential’ In California … For Now; COVID-19 Event Impacts; Cosmetics News In Brief
Santa Monica, CA-based law firm Conkle, Kremer and Engle warns that while all personal-care product businesses appear to be designated “essential” in the Golden State under its statewide “stay at home” order, officials could decide that the policy does not apply to manufacturers of non-hygiene products. More cosmetics news in brief.
Pink Sheet Podcast: US FDA’s Chloroquine EUA And Coronavirus Treatment Accelerator, Novartis Receives No Penalty For Zolgensma Problems
Pink Sheet reporters and editors discuss the effects of the chloroquine emergency use authorization, FDA efforts to speed coronavirus treatment development, and the agency decision against penalizing Novartis over Zolgensma’s data integrity problems.